Early modulation of circulating MicroRNAs levels in HER2-positive breast cancer patients treated with trastuzumab-based neoadjuvant therapy
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Bibliographic citation
-
In: International Journal of Molecular Sciences ; 21 (2020), 4. - Art.-Nr. 1386. - ISSN 1661-6596. - eISSN 1422-0067
- Keyword
-
Brustkrebs
Trastuzumab
Biomarker
miRNS
- Event
-
Veröffentlichung
- (where)
-
Ulm
- (who)
-
Universität Ulm
- (when)
-
2020
- Creator
-
Di Cosimo, Serena
Appierto, Valentina
Pizzamiglio, Sara
Silvestri, Marco
Baselga, José
Piccart-Gebhart, Martine J.
Huober, Jens
Izquierdo, Miguel
de la Pena, Lorena
Hilbers, Florentine S.
de Azambuja, Evandro
Untch, Michael
Pusztai, Lajos
Pritchard, Kathleen
Nuciforo, Paolo
Vincent-Salomon, Anne
Symmans, Fraser
Apolone, Giovanni
de Braud, Filippo G.
Iorio, Marilena V.
Verderio, Paolo
Daidone, Maria Grazia
- DOI
-
10.18725/OPARU-47911
- URN
-
urn:nbn:de:bsz:289-oparu-47987-1
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:55 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Di Cosimo, Serena
- Appierto, Valentina
- Pizzamiglio, Sara
- Silvestri, Marco
- Baselga, José
- Piccart-Gebhart, Martine J.
- Huober, Jens
- Izquierdo, Miguel
- de la Pena, Lorena
- Hilbers, Florentine S.
- de Azambuja, Evandro
- Untch, Michael
- Pusztai, Lajos
- Pritchard, Kathleen
- Nuciforo, Paolo
- Vincent-Salomon, Anne
- Symmans, Fraser
- Apolone, Giovanni
- de Braud, Filippo G.
- Iorio, Marilena V.
- Verderio, Paolo
- Daidone, Maria Grazia
- Universität Ulm
Time of origin
- 2020
Other Objects (12)
Immunzytochemischer Nachweis von Tumorzellen im Knochenmark mittels monoklonaler Antikörper bei Mammakarzinompatientinnen zum Zeitpunkt der Primärtherapie
Adjuvant trastuzumab emtansine in HER2-positive breast cancer patients with HER2-negative residual invasive disease in KATHERINE
Sind alle Anthrazykline gleich? : Stellenwert des pegylierten liposomalen Doxorubicins beim metastasierten Mammakarzinom im klinischen Alltag
Intrinsic Subtypes of Primary Breast Cancer - Gene Expression Analysis
Trastuzumab Deruxtecan: A Quantum Leap in HER2‑Positive Breast Cancer
Genomic characteristics of trastuzumab-resistant Her2-positive metastatic breast cancer
CMTM6 overexpression confers trastuzumab resistance in HER2-positive breast cancer
Trastuzumab (Herceptin (R)): monoclonal antibody in the treatment of HER2/neu-overexpressing breast cancer in the metastatic and (neo)adjuvant situation
Prognostic impact of HER2 biomarker levels in trastuzumab-treated early HER2-positive breast cancer
TRAF4 hyperactivates HER2 signaling and contributes to Trastuzumab resistance in HER2-positive breast cancer
Correction: CMTM6 overexpression confers trastuzumab resistance in HER2‑positive breast cancer
Aromatase inhibitors in the treatment of elderly women with metastatic breast cancer
Immunzytochemischer Nachweis von Tumorzellen im Knochenmark mittels monoklonaler Antikörper bei Mammakarzinompatientinnen zum Zeitpunkt der Primärtherapie
Adjuvant trastuzumab emtansine in HER2-positive breast cancer patients with HER2-negative residual invasive disease in KATHERINE
Sind alle Anthrazykline gleich? : Stellenwert des pegylierten liposomalen Doxorubicins beim metastasierten Mammakarzinom im klinischen Alltag
Intrinsic Subtypes of Primary Breast Cancer - Gene Expression Analysis
Trastuzumab Deruxtecan: A Quantum Leap in HER2‑Positive Breast Cancer
Genomic characteristics of trastuzumab-resistant Her2-positive metastatic breast cancer
CMTM6 overexpression confers trastuzumab resistance in HER2-positive breast cancer
Trastuzumab (Herceptin (R)): monoclonal antibody in the treatment of HER2/neu-overexpressing breast cancer in the metastatic and (neo)adjuvant situation
Prognostic impact of HER2 biomarker levels in trastuzumab-treated early HER2-positive breast cancer
TRAF4 hyperactivates HER2 signaling and contributes to Trastuzumab resistance in HER2-positive breast cancer
Correction: CMTM6 overexpression confers trastuzumab resistance in HER2‑positive breast cancer
Aromatase inhibitors in the treatment of elderly women with metastatic breast cancer
Immunzytochemischer Nachweis von Tumorzellen im Knochenmark mittels monoklonaler Antikörper bei Mammakarzinompatientinnen zum Zeitpunkt der Primärtherapie
Adjuvant trastuzumab emtansine in HER2-positive breast cancer patients with HER2-negative residual invasive disease in KATHERINE
Sind alle Anthrazykline gleich? : Stellenwert des pegylierten liposomalen Doxorubicins beim metastasierten Mammakarzinom im klinischen Alltag
Intrinsic Subtypes of Primary Breast Cancer - Gene Expression Analysis
Trastuzumab Deruxtecan: A Quantum Leap in HER2‑Positive Breast Cancer
Genomic characteristics of trastuzumab-resistant Her2-positive metastatic breast cancer
CMTM6 overexpression confers trastuzumab resistance in HER2-positive breast cancer
Trastuzumab (Herceptin (R)): monoclonal antibody in the treatment of HER2/neu-overexpressing breast cancer in the metastatic and (neo)adjuvant situation
Prognostic impact of HER2 biomarker levels in trastuzumab-treated early HER2-positive breast cancer
TRAF4 hyperactivates HER2 signaling and contributes to Trastuzumab resistance in HER2-positive breast cancer
Correction: CMTM6 overexpression confers trastuzumab resistance in HER2‑positive breast cancer